2D
2DT.F Amneal Pharmaceuticals Inc
- Market cap
- EUR 6.48B
- P/E
- 54.7x
- P/B
- 13.54x
- ROE
- 24.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 2DT.F undervalued?
Graham numberThe Graham number of Amneal Pharmaceuticals Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amneal Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Amneal Pharmaceuticals Inc yet.
Amneal Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, …
Full company profileAmneal Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Amneal Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.02B | 1.03B | 1.66B | 1.63B | 1.99B | 2.09B | 2.21B | 2.39B | 2.79B | 3.02B | 3.18B |
| Gross Profit | 597M | 526M | 716M | 353M | 628M | 769M | 785M | 821M | 1.02B | 1.11B | 1.32B |
| Operating Income | 274M | 225M | 236M | -186M | 108M | 193M | 189M | 239M | 348M | 398M | 558M |
| EBITDA | - | 288M | 78.3M | 155M | 346M | 401M | 150M | 400M | 440M | 604M | 637M |
| Net Income | 207M | 168M | -170M | -362M | 91.1M | 10.6M | -130M | -84.0M | -117M | 72.1M | 131M |
| EPS | - | 1.46 | -1.33 | -2.46 | 0.62 | 0.07 | -0.86 | -0.27 | -0.38 | 0.23 | 0.38 |
| Balance Sheet | |||||||||||
| Total Assets | - | 1.34B | 4.35B | 3.67B | 4.01B | 3.94B | 3.80B | 3.47B | 3.50B | 3.68B | 5.27B |
| Total Liabilities | - | 1.72B | 3.46B | 3.32B | 3.66B | 3.57B | 3.59B | 3.45B | 3.61B | 3.75B | 4.74B |
| Shareholders' Equity | - | -386M | 505M | 232M | 345M | 360M | 184M | 19.8M | -109M | -70.8M | 531M |
| Cash & Short-term Investments | - | 74.2M | 213M | 151M | 341M | 248M | 26.0M | 91.5M | 111M | 282M | 157M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 115M | 234M | 250M | 1.71M | 379M | 242M | 65.1M | 346M | 295M | 340M | 67.1M |
| Capital Expenditure | 125M | 94.8M | 83.1M | 47.2M | 61.8M | 50.9M | 48.8M | 69.2M | 75.0M | 114M | 261M |
| Free Cash Flow | - | 120M | 153M | -95.7M | 313M | 189M | -25.5M | 276M | 220M | 226M | -194M |
| Ratios | |||||||||||
| ROE | - | - | -33.6% | -156.0% | 26.4% | 2.9% | -70.7% | -424.6% | - | - | 24.7% |
| ROA | - | 12.5% | -3.9% | -9.9% | 2.3% | 0.3% | -3.4% | -2.4% | -3.3% | 2.0% | 2.5% |
| Net Profit Margin | 20.4% | 16.2% | -10.2% | -22.3% | 4.6% | 0.5% | -5.9% | -3.5% | -4.2% | 2.4% | 4.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Amneal Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 183M | 1.44 | - |
| 2017 | USD 375M | 3.27 | 223.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Amneal Pharmaceuticals Inc
- Insiders 52.08%
- Institutions 47.92%
- Public & others 0.00%
- Shares outstanding 348M
- Free float 215M
Amneal Pharmaceuticals Inc company profile
- Company name
- Amneal Pharmaceuticals Inc
- Ticker
- 2DT.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 8,700
- Fiscal year end
- December
- Address
- 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807
- Phone
- 908 947 3120
- Website
- amneal.com
About Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Amneal Pharmaceuticals Inc management
10- Mr. Chirag K. PatelCo-Founder, Co-CEO, President & Director · born 1967
- Mr. Chintu Patel R.Ph.Co-Founder, Co-CEO & Director · born 1972
- Mr. Anastasios G. KonidarisExecutive VP & CFO · born 1967
- Mr. Jason B. Daly Esq.Executive VP, Chief Legal Officer & Corporate Secretary · born 1974
- Ms. Nikita ShahExecutive VP & Chief Human Resources Officer · born 1978
- Mr. Andrew S. BoyerExecutive VP and Chief Commercial Officer of Generics & Biosciences · born 1966
- Mr. Anthony DiMeoHead/VP of Investor Relations
- Brandon SkopSenior Director of Corporate Communications
- Mr. Gregory SgammatoSenior Vice President of Corporate Development
- Mr. Pranav MehtaSenior VP of Strategic Sourcing & Supply Management